Sleep architecture and cognitive changes in olanzapine-treated patients with depression: A double blind randomized placebo controlled trial
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Disturbance in sleep quality is a symptom of Major Depressive Disorder (MDD) and Bipolar Disorder (BD) and thus improving quality of sleep is an important aspect of successful treatment. Here, a prospective, double-blind, randomized, placebo-controlled study examined the effect of olanzapine (an atypical antipsychotic) augmentation therapy on sleep architecture, specifically slow wave sleep (SWS), in the treatment of depression. The effect of olanzapine augmentation therapy on other features of sleep (e.g., sleep continuity) and depression (e.g., illness severity and cognitive function) were also determined. Methods: Patients currently experiencing a major depressive episode and who were on a stable medication were included. Sleep architecture was measured by overnight ambulatory polysomnography. Illness severity was determined using the Montgomery-Asberg Depression Rating Scale (MADRS). Cognitive function was examined using Cambridge Neuropsychological Test Automated Battery (CANTAB): Spatial Working Memory (SWM), Spatial Span (SSP), and Reaction Time (RTI) tasks. Polysomnographs, clinical measures and cognitive tests were administered at baseline, after 2–4 days of treatment and after 28–31 days of treatment. Twenty-five patients participated in the study (N = 10, N = 15 for placebo and olanzapine treated groups respectively). Results: The primary objective of the study was to assess the objective (polysomnographic) changes in sleep quality, defined as changes in SWS, following olanzapine treatment for depression. Latency to but not duration of SWS was found to significantly differ between olanzapine- and placebo-treated participants (Hedge’s g: 0.97, 0.13 respectively). A significant improvement in olanzapine-treated participants over placebo-treated participants was observed in secondary outcome measures, including sleep efficiency, total sleep time, and sleep latency. Secondary objectives assessed the subjective changes in sleep quality parameters and correlated them with measures of illness severity and changes in cognition. MADRS scores were significantly improved in olanzapine-treated participants over time but not more than placebo treatment. There was no significant difference between olanzapine- and placebo-treated participants in SWM, SSP or RTI tasks. Conclusions: Olanzapine augmentation treatment generally did not improve SWS but did improve sleep continuity and depression. Olanzapine may be one of few medications that improve sleep continuity, thus directly targeting symptoms of depression. Trial registration: ClinicalTrials.gov, NCT00520507.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The sleep switch: hypothalamic control of sleep and wakefulness
Saper, C. B., Chou, T. C., & Scammell, T. E. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02002-6 · Cited by 1,656
Behavioral and Physiological Consequences of Sleep Restriction
Banks, S., & Dinges, D. F. (2007) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26918 · Cited by 1,505 · cited 6×
“Acute and chronic sleep deprivation has been shown to affect attention, working memory and cognitive function [19-22].”
BackgroundInfluentialSleep and Psychiatric Disorders: A Meta-analysis
Benca, R. M. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080059010 · Cited by 1,468 · cited 18×
“This is the most prevalent stage of the sleep cycle in the first third of the night, approximately 10%-15% of total sleep time (TST).”
BackgroundInfluentialRobbins, T. W., James, M., Owen, A. M., Sahakian, B. J., McInnes, L., & Rabbitt, P. (1994) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106735 · Cited by 1,078
Manber, R., Edinger, J. D., Gress, J. L., Pedro-Salcedo, M. G. S., Kuo, T. F., & Kalista, T. (2008) · Sleep · doi:10.1093/sleep/31.4.489 · Cited by 868
Elliott, R., Sahakian, B. J., McKay, A. P., Herrod, J. J., Robbins, T. W., & Paykel, E. S. (1996) · Psychological Medicine · doi:10.1017/s0033291700035303 · Cited by 469
Frontal lobe function, sleep loss and fragmented sleep
Jones, K., & Harrison, Y. (2001) · Sleep Medicine Reviews · doi:10.1053/smrv.2001.0203 · Cited by 390
Cognitive disturbance in outpatient depressed younger adults: evidence of modest impairment
Grant, M. M., Thase, M. E., & Sweeney, J. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01072-6 · Cited by 319
Evidence for continuing neuropsychological impairments in depression
Weiland-Fiedler, P., Erickson, K., Waldeck, T., Luckenbaugh, D. A., Pike, D., Bonne, O., Charney, D. S., & Neumeister, A. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2003.10.009 · Cited by 314 · cited 16×
“The study by Sharpley et al. [13] included only patients with treatment resistant (to SSRI’s) MDD, and olanzapine was administered open-label with no control or comparison group.”
BackgroundInfluentialNeuropsychological function in young patients with unipolar major depression
PURCELL, R., MARUFF, P., KYRIOS, M., & PANTELIS, C. (1997) · Psychological Medicine · doi:10.1017/s0033291797005448 · Cited by 281
Cited by
Wilson, S., Anderson, K., Baldwin, D., Dijk, D.-J., Espie, A., Espie, C., Gringras, P., Krystal, A., Nutt, D., Selsick, H., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855343 · Cited by 312
Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management
Chakrabarty, T., Hadjipavlou, G., & Lam, R. W. (2016) · Focus · doi:10.1176/appi.focus.20150043 · Cited by 84
24-h activity rhythm and sleep in depressed outpatients
Hori, H., Koga, N., Hidese, S., Nagashima, A., Kim, Y., Higuchi, T., & Kunugi, H. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.02.022 · Cited by 78
Light exposure at night and sleep quality in bipolar disorder: the APPLE cohort study
Esaki, Y., Kitajima, T., Obayashi, K., Saeki, K., Fujita, K., & Iwata, N. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.031 · Cited by 45
Metadata
- Authors
- Lazowski, L. K., Townsend, B., Hawken, E. R., Jokic, R., du Toit, R., & Milev, R.
- Venue
- BMC Psychiatry
- Published
- 2014-07-17
- Volume
- 14
- Issue
- 1
- Pages
- 202-202
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W2082854118
- Cited by
- 44
- References
- 18
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sleep architecture and cognitive changes in olanzapine-treated patients with depression: A double blind randomized placebo controlled trial. https://app.cochat.ai/papers/10.1186/1471-244x-14-202
- The paper
- Lazowski, L. K., Townsend, B., Hawken, E. R., Jokic, R., du Toit, R., & Milev, R. (2014). Sleep architecture and cognitive changes in olanzapine-treated patients with depression: A double blind randomized placebo controlled trial. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-202
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.